IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Endo International plc (“Endo” or the “Company”) (Nasdaq: ENDP). Investors who purchased or otherwise acquired shares between March 2, 2015 and May 6, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm prior to the July 25, 2016, lead plaintiff motion deadline.
If you purchased shares of Endo during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company failed to disclose that: (1) Endo’s arrangements with PBMs with respect to the migraine therapy Frova included questionable incentives intended to increase sales revenues; and (2) as a result, Endo’s revenues and revenue projections relied in part on unsustainable arrangements.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.